Skye Bioscience, Inc. (SKYE)

Skye Bioscience's stock has been impacted by several events in the past six months. The Q2 2025 earnings report showed increased R&D expenses and a net loss, leading to a stock decrease. Promising preclinical results for nimacimab were announced. Phase 2a trial data for nimacimab showed it did not meet its primary endpoint as a monotherapy, but achieved additional weight loss in combination with semaglutide. JMP Securities reiterated a "Market Outperform" rating, and Skye has a consensus rating of Moderate Buy. Recent positive data from a Phase 2a extension study led to a gain in SKYE shares.

As a clinical-stage biopharmaceutical company, Skye Bioscience does not currently experience demand seasonality for its products, as they are still in clinical trials. Future demand will likely be driven by medical need and market adoption.

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel treatments, primarily cannabinoid-based molecules and GPCR modulators. The company operates in the biotechnology and pharmaceutical sector, addressing obesity, overweight, metabolic diseases, and ocular conditions. Key product candidates include Nimacimab, an antibody targeting CB1 for obesity and cardiometabolic diseases, SBI-100 Ophthalmic Emulsion, a CB1 agonist for glaucoma and ocular hypertension, and SBI-200, in development for various eye diseases.

Skye Bioscience, Inc. is headquartered in San Diego, California. It also owns a research facility in Langley, British Columbia, Canada, acquired from Emerald Health Therapeutics, Inc., which holds a dealer's license for research on controlled substances but is currently not operational.

Skye Bioscience's brand reputation has been influenced by clinical trial results and financial news. Social media discussions following the Q2 2025 earnings report showed cautious optimism. The failure of nimacimab as a monotherapy in the Phase 2a trial negatively impacted investor sentiment. Securities lawsuit filings against Skye Bioscience may also negatively affect the company's brand reputation.

As of September 2025, 59 institutional investors held 65.6% of Skye Bioscience's shares. As of February 2, 2026, there are 81 institutional owners holding a total of 20,066,404 shares. Major institutional owners include 5AM Venture Management, LLC, Versant Venture Management, LLC, Baker Bros. Advisors LP, and others. Andrew Schwab is noted as owning the most shares among individual owners.